摘要
LGR5是7次跨膜G蛋白偶联受体(G protein-coupled receptor,GPCR)超家族成员,在结直肠癌中高表达。研究发现,LGR5是结直肠癌干细胞的标志物,其异常表达能够促进结直肠癌的进展和转移,被认为是重要的结直肠癌预后不良分子。LGR5主要通过Wnt/β-catenin通路参与结直肠癌的发生发展,近年来针对该靶点的治疗研究不断增加。虽然靶向LGR5的ADCs类药物在治疗结直肠癌后存在复发的情况,但是联合用药使治疗结直肠癌的效果显著提升。该文综述了LGR5在结直肠癌中的作用机制及靶向治疗进展,表明靶向LGR5联合用药对于结直肠癌患者个性化治疗具有潜在的应用价值。
LGR5 is a member of the seven transmembrane G protein-coupled receptor(GPCR)superfamily and is highly expressed in colorectal cancer.Studies have shown that LGR5 is a marker of colorectal cancer stem cells and its abnormal expression can promote the progression and metastasis of colorectal cancer,which is considered to be a poor prognostic molecule of colorectal cancer.LGR5 is mainly involved in the development of colorectal cancer through Wnt/β-catenin pathway,and the therapeutic researches targeting LGR5 have been increasing in recent years.Although partial treatments of colorectal cancer by ADCs drugs targeting LGR5 have recurrenced,combination therapy has significantly improved the efficacy of treatment.Here we review the role of LGR5 in colorectal cancer and its progress of targeted therapy.We indicate that targeting LGR5 combination therapy has potential value for colorectal cancer patients for personalized treatment.
作者
彭立雄
常江
张博威
胡学渝
谭忠鹏
柳增善
胡盼
PENG Li-Xiong;CHANG Jiang;ZHANG Bo-Wei;HU Xue-Yu;TAN Zhong-Peng;LIU Zeng-Shan;HU Pan(College of Veterinary Medicine,Jilin University,Changchun 130062,China;Key Laboratory of Zoonosis Research,Ministry of Education/Institute of Zoonosis,Jilin University,Changchun 130062,China)
出处
《生命科学》
CSCD
北大核心
2021年第10期1231-1238,共8页
Chinese Bulletin of Life Sciences
基金
吉林省科技发展计划重点研发项目(2020-0404123YY)。
